Edwards Lifesciences has secured an important reimbursement development for its largest franchise after the Centers for Medicare & Medicaid Services issued an updated national coverage determination for transcatheter aortic valve replacement on September 10. The policy removes Coverage with Evidence Development requirements for symptomatic severe aortic stenosis and establishes coverage provisions for certain asymptomatic severe aortic stenosis patients participating in qualifying clinical studies.
The decision has particular strategic significance for Edwards because the company itself formally requested the CMS reconsideration in December 2025. CMS subsequently received 171 comments during its first public-comment period and another 257 following the proposed decision before publishing the final memorandum.
For patients, the policy modernizes a framework created when TAVR was a much newer technology. For Edwards, it can support continued procedural expansion in the United States just as clinical evidence increasingly pushes valve intervention earlier in the course of aortic stenosis.
What exactly did Medicare change for TAVR?
CMS historically used Coverage with Evidence Development to link Medicare reimbursement for certain TAVR procedures to registry or research requirements. That mechanism helped regulators and payers gather evidence while the technology evolved.
The September 2026 decision removes those CED requirements for symptomatic severe aortic stenosis and for uses that are not FDA approved, while transitioning ongoing qualifying studies to the Investigational Device Exemption coverage pathway without interrupting Medicare coverage.
CMS also created CED provisions for TAVR in asymptomatic severe aortic stenosis under defined conditions. That is particularly relevant because the frontier of structural heart care is moving from treating patients once symptoms become obvious toward determining whether earlier intervention can prevent irreversible cardiac damage.
Edwards described the modernized policy as improving and expanding access while giving multidisciplinary heart teams greater flexibility in patient evaluation and treatment.
Why does reimbursement matter almost as much as FDA approval in TAVR?
TAVR procedures are expensive, resource-intensive interventions typically performed in older patients, making Medicare a central payer in the United States market.
FDA authorization establishes whether a device can legally be marketed for an indication. Medicare coverage determines whether a large portion of the eligible population can realistically receive it without the hospital assuming unsustainable financial risk.
For Edwards, coverage rules can therefore directly influence procedure volume.
The effect is especially important as TAVR moves into lower-risk and potentially earlier-stage patients. Every expansion of the treatment population requires reimbursement structures that allow hospitals to perform the procedure economically.
Medicare policy can also influence hospital investment in heart teams, catheterization facilities and referral networks, meaning coverage affects infrastructure as well as individual cases.
How large is TAVR for Edwards Lifesciences?
TAVR remains the economic center of Edwards Lifesciences.
The company generated approximately $1.26 billion of TAVR sales in the second quarter of 2026, representing the majority of its $1.74 billion quarterly revenue. TAVR revenue grew 11.3% year over year, or 10.5% on a constant-currency basis. Edwards subsequently increased its full-year constant-currency TAVR growth outlook to 8% to 9%.
That concentration explains why regulatory and reimbursement developments around aortic stenosis matter disproportionately to the company.
Edwards’ SAPIEN franchise has built one of medtech’s most valuable procedural businesses through a combination of implants, physician training, clinical evidence and expanding indications. Continued double-digit procedure growth can compound meaningfully because every additional eligible patient translates into potential valve revenue.
Unlike a software launch or early-stage device, the commercial pathway is already established. The question is how much larger the eligible population can become.
Why is earlier treatment becoming the next structural-heart battleground?
Aortic stenosis is progressive. Once the valve becomes severely narrowed, increased pressure can cause ventricular remodeling and irreversible cardiac damage.
Historically, physicians often waited for clear symptoms before replacing the valve. Newer evidence has raised the possibility that waiting may expose some patients to avoidable deterioration.
Edwards has been generating evidence designed to support proactive treatment. The company highlighted five-year EARLY TAVR data during its second-quarter update and is also studying broader patient groups through programs such as PROGRESS.
Medicare’s willingness to provide a research-linked coverage pathway for certain asymptomatic severe patients therefore aligns with the direction of the clinical-development program.
If future studies demonstrate convincing benefits from earlier intervention, the addressable TAVR population could increase substantially because treatment would no longer depend exclusively on patients reaching a symptomatic threshold.
What does the new policy mean for hospitals?
The updated policy gives heart teams more flexibility but does not remove the need for appropriate patient selection and infrastructure.
TAVR remains a complex structural-heart procedure requiring imaging, interventional cardiology, surgical expertise and longitudinal follow-up. Hospitals must therefore evaluate whether procedural volumes justify investment in specialized teams.
A more streamlined coverage framework may make referrals simpler and reduce administrative friction. It may also encourage additional centers to consider TAVR programs if potential procedure volumes increase.
For existing high-volume centers, the largest effect could be earlier access to patients who previously faced reimbursement complexity or were being managed conservatively.
How does this affect Edwards Lifesciences’ competitive position?
Edwards benefits from an established SAPIEN installed base and substantial long-term clinical evidence. In its second-quarter update, the company said its United States competitive position increased modestly year over year, helped by adoption of the SAPIEN 3 Ultra RESILIA platform.
Broader coverage can expand the market for all qualifying competitors rather than Edwards alone. However, the incumbent with the largest physician familiarity and evidence base can often capture a meaningful portion of incremental procedure growth.
The company is also extending beyond TAVR into transcatheter mitral and tricuspid therapies, where second-quarter TMTT sales reached $195.9 million.
That means Edwards is progressively evolving from an aortic-valve company into a wider structural-heart platform. Nevertheless, TAVR remains the financial engine funding that expansion.
What should investors watch after the CMS decision?
Procedure growth is the clearest near-term measure. If simplified coverage translates into higher referral rates or faster treatment, Edwards should begin to see the effect through United States TAVR volumes.
The second issue is uptake among asymptomatic patients enrolled through qualifying studies. Those programs can build the evidence required for future coverage expansion.
The third is the PROGRESS trial and other efforts examining intervention earlier in aortic stenosis. If clinical evidence moves the treatment threshold upstream, reimbursement policy will become even more economically consequential.
CMS has not simply rewritten paperwork around an established procedure. It has updated the reimbursement architecture at a moment when the definition of who should receive TAVR is itself changing.
For Edwards Lifesciences, that creates a favorable setup: its largest franchise is still growing at double-digit rates, Medicare has modernized access, and the clinical development strategy is attempting to make the addressable population larger again.
